This review found that amifostine did not reduce overall survival and progression-free survival in patients treated with radiotherapy or chemoradiotherapy. These conclusions should be treated with caution given the potential for missing data.
Authors' objectives
To evaluate the impact of amifostine on overall survival and progression-free survival in patients treated with radiotherapy or chemoradiotherapy
Searching
Searching was carried out without language restrictions across nine databases including MEDLINE, EMBASE and CANCERLIT. Search dates were 1966 to 2004. Handsearching was performed using review articles, meeting proceedings of five relevant conferences from 1994 to 2004 and contact with experts in the field and members of the meta-analysis steering committee. Both published and unpublished trials were eligible.
Study selection
Studies had to include randomised controlled trials (RCTs) that compared radiotherapy or chemoradiotherapy with or without amifostine for curative purposes in nonmetastatic cancers. Amifostine could only be administered during the course of radiotherapy and not afterwards. The primary outcome was overall survival and the secondary outcome was progression-free survival.
Across the analysed trials, 73% of patients were male, 90% had late stage and 10% early stage disease; 33% had lung cancer, 65% head and neck and 2% cervix uteri carcinoma. Amifostine was administered intravenously in 92% of cases. Three quarters of the included trials and over half of the patients received chemoradiotherapy, the rest radiotherapy.
It was unclear how many reviewers were involved in study selection for the review.
Assessment of study quality
All the data were checked for internal consistency and compared with the trial's protocol and published reports. Standard checks were performed for quantification of missing data and to check data quality and consistency.
It was unclear how many reviewers were involved in this process.
Data extraction
Individual patient data were obtained from the trialists. Data on patients excluded after randomisation was sought. Each trial was analysed before being sent back to the trialists for review. For each trial a hazard ratio (HR) was calculated based on observed minus expected deaths and associated variance.
It was unclear how many reviewers were involved in data extraction for the review.
Methods of synthesis
Intention-to-treat analysis was used. Patients alive without disease were censored on the last date of follow-up. A fixedeffect model of meta-analysis was used with trials weighted according to variance in observed minus expected deaths. Χ² and Ι² tests were used to assess heterogeneity between trials. Pooled hazard ratios and 95% confidence intervals (CI) were calculated. Hazard ratios and 95% confidence intervals were also calculated for investigation of the interaction between treatment and a covariate. Survival curves were calculated for control and experimental groups and used to calculate absolute difference at two and five years.
